Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CKD-508 in Healthy Participants
NCT06727396Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Nov 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CKD-508 in hypercholesterolemia, sponsored by Chong Kun Dang Holdings. Primary endpoints: Treatment-Emergent Adverse Event at Day 56, Maximum Plasma Concentration at Day 56 and 4 more. Started Nov 2024; status: completed.
02
Drugs
CKD-508
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT06727396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06727396.